Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 74Breast Neoplasms 70Rectal Neoplasms 51Stomach Neoplasms 45Glioblastoma 45Esophageal Neoplasms 41Colorectal Neoplasms 37Lung Neoplasms 35Brain Neoplasms 35Squamous Cell Carcinoma of Head and Neck 32Pancreatic Neoplasms 31Glioma 27Neoplasms 26Sarcoma 24Neoplasm Metastasis 23Astrocytoma 22Head and Neck Neoplasms 21Carcinoma, Hepatocellular 19Esophageal Squamous Cell Carcinoma 16Colonic Neoplasms 16Recurrence 15Ovarian Neoplasms 15Melanoma 15Gliosarcoma 15Central Nervous System Neoplasms 15Urinary Bladder Neoplasms 13Oligodendroglioma 13Uterine Cervical Neoplasms 12Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 11

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Non-small Cell Lung Cancer × Surgical Procedures, Operative × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡